Literature DB >> 1615488

Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels.

I Juhan-Vague1, M C Alessi, D Raccah, M F Aillaud, M Billerey, J Ansaldi, C Philip-Joet, P Vague.   

Abstract

The mechanism underlying diurnal variations in PAI-1 as well as the cellular origin of PAI-1 in subjects with high PAI-1 levels are unknown. We evaluated diurnal changes (8:00 am vs 4:00 pm) in PAI-1 (functional and immunological assays), t-PA Ag and t-PA/PAI-1 complex levels in controls and subjects with high PAI-1 levels. Three test groups were recruited among obese hyperinsulinemic subjects, emergency care unit patients with inflammatory syndrome or infection and pregnant women. The classical afternoon decrease of PAI-1 level was observed in controls and obese subjects but its amplitude was greater in the latter. The decrease in t-PA Ag and t-PA/PAI-1 complex levels was the same in controls and in obese. As, in previous studies, elevated PAI-1 levels have been correlated with insulin resistance and a decrease in insulin sensibility has been described in the early morning, it is proposed that this "dawn phenomenon" could be implicated in the circadian variations of PAI-1 in controls and could be amplified in obese subjects. Great variability in PAI-1, t-PA Ag or t-PA/PAI-1 complex levels was observed in patients with acute inflammatory syndrome or infection for whom classical biorhythms are suppressed. No diurnal changes in PAI-1 and other fibrinolytic parameters were observed in patients with inflammatory syndrome or in pregnant women suggesting that other sources and/or other regulatory mechanisms of PAI-1 production are involved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615488

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

2.  Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea.

Authors:  Kanika Bagai; James A S Muldowney; Yanna Song; Lily Wang; Jayant Bagai; Kay J Artibee; Douglas E Vaughan; Beth A Malow
Journal:  Sleep       Date:  2014-02-01       Impact factor: 5.849

3.  Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.

Authors:  Katarina Lalić; Aleksandra Jotić; Nataša Rajković; Sandra Singh; Ljubica Stošić; Ljiljana Popović; Ljiljana Lukić; Tanja Miličić; Jelena P Seferović; Marija Maćešić; Jelena Stanarčić; Milorad Čivčić; Iva Kadić; Nebojša M Lalić
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

4.  Validation of an immunoassay to measure plasminogen-activator inhibitor-1 concentrations in human saliva.

Authors:  Xi Zhang; Goce Dimeski; Chamindie Punyadeera
Journal:  Biochem Med (Zagreb)       Date:  2014-06-15       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.